Our April Speaker Series, “Beyond the Pill” focuses on the relationship between pharma, patients, providers and digital health.
During our panel we plan to explore the following questions:
What are some of the things we are currently seeing in pharma and digital health? What is the industry interested in doing more of? What are some of the current challenges when it comes to pharma and digital health? Where are the gaps on within both pharma and patient care, and how do we close them? How do we find a way for these opportunities and challenges to become opportunities to work together? How can we collaborate together beyond the pill?
Panel Members: Matt Schumacher, UCB
Aman Bhandari, Merck
Luba Greenwood, Roche
Rachel Sha, Sanofi
Moderator: Naomi Fried, Health Innovation Strategies
When: April 25th, 5:00 p.m.- 6:00 p.m.
Where: First Floor Cafe, BTM
Speaker: 5:00 p.m. - 6:00 p.m.
Networking: 6:00 p.m. - 6:30pm
Appetizers, beer and wine will be provided.
Matt Schumacher, UCB
Matt Schumacher is Patient Mission Lead at UCB Inc. providing regional connectivity between UCB and health systems to catalyze new solutions for patients with epilepsy. He has served on the movement marketing team focused on developing resources for patients suffering from Parkinson’s disease and was commercial lead for neurology in New England. Prior to that, Matt provided leadership at Sanofi to five different sales teams in rheumatology, cardiology, endocrinology, and internal medicine for 10 years. His professional experience includes development and fundraising at Colby College as Major Gift Officer and Harvard Business School as Assistant Director of the HBS Fund.
Matt earned his B.A. in Biochemistry, with distinction, from Wheaton College (MA) in 1998, where he was also elected President of the Student Government Association. Matt currently serves on the Yarmouth (ME) Planning Board. His past civic involvement include the Yarmouth Historical Society and American Institute of Graphic Arts.
Aman Bhandari, Merck
Aman Bhandari, PhD is currently at Merck Research Labs in the Longwood Medical Area, where he heads up a unit focused on building data science partnerships and capabilities for the company. Prior to Merck, he worked at the White House for President Obama’s first two U.S. Chief Technology Officers as well as a senior research scientist at the Centers for Medicare and Medicaid Services.
Luba Greenwood, Roche
Vice President of Global Mergers & Acquisitions and Business Development, F. Hoffmann-La Roche, Diagnostics, Head of Roche Diagnostics Partnering Hub
Luba Greenwood is a Vice President of Global Mergers & Acquisitions and Business Development at F. Hoffmann-La Roche, Diagnostics. She is also heading the Roche Diagnostics Partnering Hub for the East Coast. She brings over pharmaceutical and biotechnology industry experience and expertise in building and advising innovative technology companies and providing strategic counsel to global corporations. Her career has spanned leadership roles in venture capital, business development, M&A, law, consulting, and operations. Luba has recently served as a Venture Partner at Colt Ventures, and led Business Development and Strategy at a Flagship VenturesLabs company. Prior to that, Luba served as a Senior Mergers & Acquisitions Counsel at Pfizer Inc. Luba began her career practicing law at a leading national law firm, Wilmer Cutler Pickering Hale and Dorr, where she represented large multinational corporations, start-ups, and private equity and venture capital funds in biotechnology, high technology, energy, and finance industries in securities, intellectual property, regulatory, and litigation matters.
Luba is a professor at Boston University School of Management where she teaches Business Law, and Boston University Law School where she teaches a course on the Life Sciences. Luba serves on the board of the Longwood Symphony Orchestra, is a Co-chair of MassBio’s Entrepreneur’s University, mentor for the MIT 100K Entrepreneurship Competition, a judge for MassChallenge and the Young Entrepreneurs Initiative, and on a Steering Committee of the Boston Bar Association. In 2014, she received the Science Club for Girls Catalyst Award for her commitment to fostering women talent and advocating for women in science and technology.
Rachel Sha, Sanofi
Rachel Sha is the Vice President of Central Transactions and Digital BD for Business Development & Licensing at Sanofi. She leads a team of business development professionals in driving transactions from due diligence to deal closing across therapeutic areas including digital health. Recent deals she has led in digital include Science 37 which enable decentralized clinical studies. She co-led the transaction with Verily Life Sciences in diabetes and was the alliance manager to the collaboration with Verily Life Sciences and led the formation of the joint venture called Onduo.
She joined Genzyme in 2005 and has held roles of increasing responsibility in Business Development, Corporate Development, and Global Marketing & Strategy for Genzyme and Sanofi. Prior to Sanofi, Genzyme, Rachel was a manager at Accenture where she focused on a broad range of business issues from strategy to process to technology implementation across a diverse set of industries with focus in electronics & high tech in particular. Rachel holds a BS from Massachusetts Institute of Technology in Chemistry and an MBA from Harvard Business School.
Naomi Fried, Ph.D, Health Innovation Strategies
Naomi Fried Ph.D, a national thought leader on healthcare innovation, is founder and CEO of Health Innovation Strategies, a consulting firm specializing in healthcare innovation and digital health strategy. She advises pharma companies, start-ups, and providers on innovation infrastructure and management and digital health strategy.
Naomi was previously Biogen’s first VP of Innovation, Medical Information and External Partnerships. She developed Biogen’s “innovation beyond the molecule” strategy to deliver non-pharmacological value to patients and providers.
Prior to Biogen, Naomi was the first Chief Innovation Officer at Boston Children’s Hospital (BCH). At BCH, Naomi built and led the Innovation Acceleration Program, which focused on enhancing the innovation culture, improving care quality, and assisting the hospital in shaping the future of health care. The Innovation Acceleration program supported strategic innovation initiatives, resourced grass roots innovation, and identified unmet innovation opportunities. Naomi oversaw the creation and administration of the Innovestment seed grant program which supported 37 projects and the FastTrack Innovation (FIT) in Technology Program which developed 9 novel clinical software solutions and mobile apps. She also initiated and led the development of BCH’s telehealth strategy.
Before moving to the Boston area, Naomi was the VP of Innovation and Advanced Technology at Kaiser Permanente (KP) in Oakland, California, where she led an effort to identify and assess emerging health care technologies and chaired the board of its internal Innovation Fund for Technology. She formed KP’s Telehealth Working Group and was involved in the start-up and governance of KP’s Innovation lab, the Sidney R. Garfield Center for Health Care Innovation. She was the Managing Director of the Archimedes Project.
Naomi has served on the advisory boards of the HealthCare Business Women's Association, MedCity News, Digital Collaboration Solutions, the Journal of Clinical Innovation & Technology, as well as a Director of the American Telemedicine Association. She was also appointed a member of the Governor of Massachusetts’ Innovation Council. Her awards include being named one of WEST’s “Notable Women Entrepreneurs in Science & Technology” in 2013 and one of Healthcare IT News’ “2013 Health Information Technology (HIT) Men and Women of the Year Award, Innovators.” Naomi was named “The Emerging Executive of the Year” in 2014 by the Massachusetts Technology Leadership Council and was named one of 40 “Healthcare Transformers of 2016” by MM &M. Naomi writes and speaks nationally and internationally on innovation and digital health. Naomi received her Ph.D. in Materials Science from MIT and her B.S. in Chemistry from the University of California, Berkeley.